Kartik Telukuntla
Advanced Heart Failure and Transplant Cardiology · Dallas, TXNPI 1619397072
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,567 of the $79,579 with a category attached, or 61.0%. Pfizer accounts for 89.7% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $57,426, more than ten times the $125 reported in 2019.
Across 238 payments — averaging $334.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$71K
- Abbott$4K
- Itamar Medical Inc$434
- AstraZeneca$410
- Heartflow, Inc.$360
- Medtronic$305
- plus $3K from 25 others
What the payments were for
- Consulting fees$16,90021%
- Speaking & faculty fees$48,56761%
- Travel & lodging$5,1126%
- Food & beverage$9,00111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 75 | $71,365 |
| Abbott | 40 | $3,704 |
| Itamar Medical Inc | 4 | $434 |
| AstraZeneca | 10 | $410 |
| Heartflow, Inc. | 4 | $360 |
| Medtronic | 5 | $305 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $304 |
| Boehringer Ingelheim | 8 | $266 |
| Novartis | 14 | $259 |
| Alnylam Pharmaceuticals Inc. | 6 | $244 |
| Merck | 12 | $244 |
| Kestra Medical Technology Services, Inc. | 9 | $231 |
| E.r. Squibb & Sons, L.L.C. | 7 | $200 |
| Abiomed | 2 | $174 |
| Edwards Lifesciences | 1 | $166 |
| Biotronik Inc. | 1 | $164 |
| Cvrx, Inc. | 4 | $106 |
| Bridgebio Pharma, Inc. | 4 | $97 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Scpharmaceuticals Inc. | 3 | $69 |
| Lexicon Pharmaceuticals, Inc. | 3 | $60 |
| Boston Scientific | 2 | $56 |
| Impulse Dynamics (USA) Inc. | 1 | $41 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Cordis US CORP. | 1 | $29 |
| Altathera Pharmaceuticals LLC | 1 | $22 |
| Endotronix, Inc. | 1 | $22 |
| GSK | 1 | $18 |
| Recor Medical Inc | 1 | $17 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$70,295
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,621
- VYNDAMAX$843
- WatchPATONE$314
- FFRct$292
- HeartMate 3 Left Ventricular Assist Device$287
- COREVALVE EVOLUT R$254
- INSPIRIS RESILIA aortic valve$166
- BioMonitor$164
- AMVUTTRA$127
- JARDIANCE$125
- WAINUA$124
- LifeVest$116
How this compares
$79,579 in reported general payments places this provider in the 80th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 67 | $65,198 |
| EliquisApixaban | 24 | $30,368 |
| FarxigaDapagliflozin Propanediol | 37 | $25,358 |
| Metoprolol Succinate | 117 | $2,359 |
| Atorvastatin Calcium | 123 | $1,116 |
| Valsartan | 25 | $805 |
| Omega-3 Acid Ethyl Esters | 11 | $671 |
| Carvedilol | 76 | $510 |
| Furosemide | 120 | $468 |
| Rosuvastatin Calcium | 16 | $453 |
| Spironolactone | 37 | $313 |
| Losartan Potassium | 35 | $311 |
| ClopidogrelClopidogrel Bisulfate | 23 | $244 |
| Nifedipine ErNifedipine | 18 | $237 |
| Potassium Chloride | 12 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $259 | $65,19867 claims |
| PfizerEliquis | $71,365 | $30,36824 claims |
| AstraZenecaFarxiga | $410 | $25,35837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Dallas
- Robert GottliebDallas$717K
- Martin BerkDallas$379K
- Shelley HallDallas$254K
- Maryjane FarrDallas$148K
- Claudius MahrDallas$87K
- Song LiDallas$27K
- Farah Al-SaffarDallas$24K
- Srikant PatlollaDallas$23K
- Nicholas HendrenDallas$12K
- Brian HsiDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.